In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
All content for At the Intersection of Science and Law is the property of DLA Piper and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches
At the Intersection of Science and Law
29 minutes
11 months ago
Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches
In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.
At the Intersection of Science and Law
In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
